Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection

Pathog Dis. 2019 Apr 1;77(3):ftz022. doi: 10.1093/femspd/ftz022.

Abstract

Fosfomycin tromethamine (FT), an old antibiotic revived as a new strategy to overcome antibiotic resistance, is an excellent option for the treatment of lower urinary tract infection (UTI). During UTI, Escherichia coli produces biofilms and could invade the bladder epithelial cells, developing intracellular bacterial communities (IBC). The present work aimed to evaluate the activity of FT on biofilms and IBC from clinical isolates of E. coli. A total of 38 E. coli clinical UTI isolates previously characterized as biofilm and IBC producers were studied. FT susceptibility was evaluated and its activity on 48 h biofilm was determined by microtiter plate-based biofilm assay comparing three different antibiotic concentrations. Two UPEC strains were selected to evaluate FT activity on IBC in vitro using T24 bladder cells. The survival percentage of intracellular bacteria after 24 h exposure to FT was calculated and compared to the percentage of intracellular bacteria without antibiotic. All the strains were susceptible to FT. FT produced a significant reduction of biofilms at the three concentrations tested, compared to the control. However, no statistically effect on IBC was observed after 24 h of fosfomycin exposure in cell culture. FT is a good option for bacterial biofilm reduction within UTI. However, it does not affect IBC.

Keywords: antibiotic resistance; biofilms; fosfomycin tromethamine; intracellular bacterial communities; urinary tract infections; uropathogenic E. coli.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Biofilms / drug effects*
  • Biofilms / growth & development
  • Cells, Cultured
  • Child
  • Child, Preschool
  • Epithelial Cells / microbiology*
  • Escherichia coli Infections / microbiology
  • Fosfomycin / pharmacology*
  • Humans
  • Microbial Sensitivity Tests
  • Urinary Tract Infections / microbiology
  • Uropathogenic Escherichia coli / drug effects*
  • Uropathogenic Escherichia coli / growth & development
  • Uropathogenic Escherichia coli / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Fosfomycin